Nocardiosis in Quebec, Canada, 1988-2008.

Nocardia is an uncommon pathogen, but immunosuppression, its main risk factor, is becoming more frequent. We aimed to evaluate changes in the annual incidence of nocardiosis and in the susceptibility profile of its aetiological agents. Demographic data were analysed for all isolates of Nocardia forwarded to the provincial public health laboratory of Quebec, Canada during the last two decades. Population incidence could be measured from 1997 onwards. Resistance patterns were analysed for those isolates selected for in vitro susceptibility testing. Throughout Quebec, 575 incident cases were identified between 1997 and 2008. The annual incidence of Nocardia infection/colonization increased from 0.33 (1997-1998) to 0.87 (2007-2008) per 100,000 inhabitants (p 0.001). In a small subset of patients for whom detailed clinical information was available, 59% of isolates corresponded to genuine infections. Nocardia farcinica predominated in specimens representing invasive infections (blood, brain, lung or pleural aspirates). Isolates were often non-susceptible to several antimicrobials, with the exception of amikacin and linezolid. Overall, 43% of 157 isolates were non-susceptible to trimethoprim-sulphamethoxazole. In conclusion, Nocardia infection/colonization remains rare. However, from 1997-1998, a progressive increase in incidence was noted in the province of Quebec. In regions such as ours, where a substantial proportion of invasive isolates are non-susceptible in vitro to trimethoprim-sulphamethoxazole, the latter may no longer be the empirical treatment of choice in immunosuppressed and severely ill patients with nocardiosis.

[1]  P. Domingo,et al.  Infection Caused by Nocardia farcinica: Case Report and Review , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[2]  R. Wallace,,et al.  Clinical and Laboratory Features of the Nocardia spp. Based on Current Molecular Taxonomy , 2006, Clinical Microbiology Reviews.

[3]  T. Jodlowski,et al.  LInezolid for the Treatment of Nocardia spp. Infections , 2007, The Annals of pharmacotherapy.

[4]  M. Hattori,et al.  The complete genomic sequence of Nocardia farcinica IFM 10152. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Huard,et al.  Nocardia cyriacigeorgica, an Emerging Pathogen in the United States , 2007, Journal of Clinical Microbiology.

[6]  M. Vaneechoutte,et al.  Distribution of Nocardia Species in Clinical Samples and Their Routine Rapid Identification in the Laboratory , 2005, Journal of Clinical Microbiology.

[7]  E. Lederman,et al.  A Case Series and Focused Review of Nocardiosis: Clinical and Microbiologic Aspects , 2004, Medicine.

[8]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[9]  G. Filice Nocardiosis in persons with human immunodeficiency virus infection, transplant recipients, and large, geographically defined populations. , 2005, The Journal of laboratory and clinical medicine.

[10]  B. Dupont,et al.  Review of nocardial infections in France 1987 to 1990 , 1992, European Journal of Clinical Microbiology and Infectious Diseases.

[11]  Jerome J. Schentag,et al.  Clinical experience with linezolid for the treatment of nocardia infection. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. McNeil,et al.  The medically important aerobic actinomycetes: epidemiology and microbiology , 1994, Clinical Microbiology Reviews.

[13]  D. Harmsen,et al.  Phylogeny of the Genus Nocardia Based on Reassessed 16S rRNA Gene Sequences Reveals Underspeciation and Division of Strains Classified as Nocardia asteroides into Three Established Species and Two Unnamed Taxons , 2003, Journal of Clinical Microbiology.

[14]  R. Wallace,,et al.  Sequence-Based Identification of Aerobic Actinomycetes , 2004, Journal of Clinical Microbiology.

[15]  B. Beaman,et al.  Nocardia species: host-parasite relationships , 1994, Clinical Microbiology Reviews.

[16]  S. Fischer,et al.  Identification of Nocardia Species by Restriction Endonuclease Analysis of an Amplified Portion of the 16S rRNA Gene , 2000, Journal of Clinical Microbiology.

[17]  C.-C. Lai,et al.  Clinical and microbiological characteristics of Nocardiosis including those caused by emerging Nocardia species in Taiwan, 1998-2008. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  M. Saubolle,et al.  Nocardiosis , 2003, Journal of Clinical Microbiology.

[19]  D. Harmsen,et al.  Evaluation of Partial 16S Ribosomal DNA Sequencing for Identification of Nocardia Species by Using the MicroSeq 500 System with an Expanded Database , 2004, Journal of Clinical Microbiology.

[20]  E. Bouza,et al.  Nocardiosis at the Turn of the Century , 2009, Medicine.

[21]  F. Witebsky,et al.  Nocardia, Rhodococcus, Gordonia, Actinomadura, Streptomyces, and Other Aerobic Actinomycetes , 2006 .

[22]  K. Nishimura,et al.  Nocardial Infections in Japan from 1992 to 2001, Including the First Report of Infection by Nocardia transvalensis , 2003, European Journal of Epidemiology.

[23]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[24]  R. Wallace,,et al.  Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .

[25]  P. Georghiou,et al.  Infection with Nocardia species in Queensland: A review of 102 clinical isolates , 1992, The Medical journal of Australia.

[26]  Y. Glupczynski,et al.  Determination of antimicrobial susceptibility patterns of Nocardia spp. from clinical specimens by Etest. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.